What Is a GHRP?
GHRPs — Growth Hormone Releasing Peptides — are synthetic peptides that stimulate growth hormone secretion by acting at the GHS-R1a receptor (growth hormone secretagogue receptor, type 1a), also known as the ghrelin receptor. They constitute one of the two major receptor systems for GH release, the other being the GHRH receptor activated by GHRH and its analogs.Unlike GHRH analogs (sermorelin, CJC-1295, tesamorelin), which are structurally related to the endogenous GHRH peptide, GHRPs were developed synthetically as ghrelin-mimetics — they mimic ghrelin's GH-releasing action at GHS-R1a without reproducing the full ghrelin sequence.
GHRPs are typically studied in combination with GHRH analogs to engage both receptor systems simultaneously and generate synergistic GH pulses. The four most widely published GHRPs are:
1. Ipamorelin — the most selective
2. GHRP-6 — the original benchmark
3. GHRP-2 — potent but less selective than ipamorelin
4. Hexarelin — most potent; engages additional cardiac receptors
---
Individual GHRP Profiles
Ipamorelin
Structure: Synthetic pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 amino acids) Primary receptor: GHS-R1a (highly selective) GH selectivity: Ipamorelin was designed specifically for GH selectivity. At research-relevant concentrations, it does not significantly elevate cortisol, prolactin, ACTH, or TSH. This selectivity makes it the preferred GHRP when researchers need to study GH-axis effects in isolation, without stress-axis activation confounding the experimental design. Half-life: ~2 hours Key research applications: Pituitary somatotroph biology, pulsatile GH dynamics, GHRH+GHRP synergy studies, aging and somatopause models, appetite/hypothalamic ghrelin-receptor research Phase 1 Peptides stocks: Ipamorelin. See also the Ipamorelin research primer.---
GHRP-6
Structure: Synthetic hexapeptide — His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (6 amino acids) Primary receptor: GHS-R1a (with off-target activity) GH selectivity: GHRP-6 is the original benchmark GHRP and has the most published literature of any compound in this class. However, it lacks the selectivity of ipamorelin: at GH-releasing concentrations, GHRP-6 produces significant elevation of cortisol and prolactin through off-target receptor mechanisms not fully characterized. This complicates research designs where clean GH measurement is required. Half-life: 15–60 minutes (rapid plasma clearance) Appetite effects: GHRP-6 is notable for strong appetite stimulation in animal models — a ghrelin-mimetic effect distinct from its GH-releasing action and mediated by central GHS-R1a expression in hypothalamic feeding-regulation circuits. Key research applications: Benchmark GHRP for historical comparison, GH pulse studies where cortisol confounders are acceptable or controlled for, appetite and orexigenic research---
GHRP-2
Structure: Synthetic hexapeptide — D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ (6 amino acids) Primary receptor: GHS-R1a (with off-target activity) GH selectivity: GHRP-2 produces stronger GH release per unit dose than GHRP-6 in direct comparison studies, but retains the cortisol and prolactin elevation characteristic of first-generation GHRPs. The off-target activity profile is qualitatively similar to GHRP-6 — less selective than ipamorelin — but the peak GH amplitude is higher. Half-life: ~30–60 minutes Key research applications: High-amplitude GH pulse studies, potency comparisons across GHRPs, GH-axis challenge protocols---
Hexarelin
Structure: Synthetic hexapeptide — His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂ (6 amino acids; His-D-2-methyltryptophan variant) Primary receptor: GHS-R1a + CD36 (scavenger receptor) GH selectivity: Hexarelin is the most potent GHS-R1a agonist of the four and produces the largest GH pulse amplitudes. However, it also engages CD36 — a scavenger receptor expressed on cardiac tissue, macrophages, and endothelium — independently of GHS-R1a. This additional receptor interaction is what makes hexarelin the preferred research tool for GHS-R1a cardiac biology studies, where CD36-mediated cardioprotective effects are themselves an endpoint of interest. Half-life: ~30 minutes (rapid clearance) Key research applications: Cardiac GHS-R research, CD36 receptor biology, high-potency GH stimulation benchmarks, ischemia-reperfusion cardiac models---
Comparison Matrix
| Feature | Ipamorelin | GHRP-6 | GHRP-2 | Hexarelin |
| Structure | Pentapeptide | Hexapeptide | Hexapeptide | Hexapeptide |
| GHS-R1a selectivity | High | Moderate | Moderate | High (+ CD36) |
| GH release potency | Moderate | Moderate | High | Very high |
| Cortisol elevation | Minimal | Significant | Moderate | Moderate |
| Prolactin elevation | Minimal | Significant | Moderate | Moderate |
| Appetite stimulation | Minimal | Strong | Moderate | Moderate |
| Additional receptor activity | None | None | None | CD36 |
| Plasma half-life | ~2 hours | 15–60 min | 30–60 min | ~30 min |
| Primary research use | GH selectivity, pulsatile GH | Benchmark GHRP | Potency comparator | Cardiac GHS-R, CD36 |
| Best for | Clean GH-axis studies | Historical comparisons | High-amplitude GH | Cardiac research |
---
Choosing the Right GHRP for Study Design
Use ipamorelin when:- GH elevation must be isolated from cortisol/prolactin confounders
- Research design uses repeated measurements where stress-axis activation would bias endpoints
- Pairing with a GHRH analog (CJC-1295, sermorelin) for dual-pathway synergy
- Studying pulsatile GH dynamics across multiple timepoints
- Historical comparison with published literature is required (GHRP-6 has the largest published dataset)
- Appetite/orexigenic hypothalamic mechanisms are themselves study endpoints
- Cortisol/prolactin elevation is expected and controlled for in the design
- Maximum GH amplitude is the research objective and selectivity is less critical
- Dose-response comparisons across GHRP potency spectrum are needed
- Cardiac GHS-R1a biology is the study target
- CD36-mediated cardioprotective mechanisms are endpoints
- Maximum receptor stimulation benchmarking is required
---
GHRH + GHRP Synergy
All four GHRPs work synergistically with GHRH analogs. The two receptor systems:
- GHRHR (activated by GHRH/sermorelin/CJC-1295/tesamorelin): cAMP signaling pathway
- GHS-R1a (activated by all four GHRPs): IP3/DAG calcium mobilization
The two pathways converge on somatotroph calcium signaling through independent intracellular mediators. Co-activation produces a synergistic GH pulse substantially larger than either receptor alone — the pharmacological rationale behind the well-replicated CJC-1295 + Ipamorelin research combination.
For GHRH analog comparison across sermorelin, CJC-1295 No DAC, CJC-1295 DAC, and tesamorelin, see the GHRH Analog Comparison.
---
Individual Compound Primers
- Ipamorelin: Selective GHRP Pharmacology
- CJC-1295 & Ipamorelin: GHRH + GHRP Research
- GHRH Analog Comparison: Sermorelin, CJC-1295, Tesamorelin
---
Summary
The four canonical GHRPs — ipamorelin, GHRP-6, GHRP-2, and hexarelin — share GHS-R1a as their primary mechanism but differ substantially in selectivity, potency, off-target effects, and research application contexts. Ipamorelin's clean GH selectivity makes it the most versatile research GHRP where isolated GH-axis measurement is required. GHRP-6 remains the benchmark with the largest historical dataset. GHRP-2 provides higher GH amplitudes for studies where potency is the variable. Hexarelin is the tool of choice for cardiac GHS-R and CD36 receptor biology. All four are studied in combination with GHRH analogs for synergistic dual-pathway GH release.
---
Common Questions
Q: What is the key pharmacological difference between ipamorelin and GHRP-6?Ipamorelin binds GHS-R1a with high selectivity for GH secretion, producing minimal co-release of cortisol or prolactin. GHRP-6 also binds GHS-R1a but with broader off-target effects — it has documented orexigenic (appetite-stimulating) activity at hypothalamic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways, and produces measurable cortisol and prolactin elevation in published pharmacology studies. For research designs where isolated GH-axis measurement is required, ipamorelin's selectivity profile is the standard choice.
Q: Why does GHRP-6 remain the most-cited GHRP in the published literature despite ipamorelin's selectivity advantages?GHRP-6 was the first synthetic hexapeptide GH secretagogue and has a 30+ year published research history across animal models, human pharmacology studies, and GH axis investigations. Published dose-response curves, reference ranges, and experimental protocols using GHRP-6 are extensive. Ipamorelin was developed later — it was designed to improve on GHRP-6's selectivity profile. Researchers requiring comparison with historical literature often use GHRP-6 specifically to match prior study conditions.
Q: How do GHRPs and GHRH analogs synergize in research models?GHRPs act at GHS-R1a, signaling through IP3/DAG-mediated intracellular calcium mobilization. GHRH analogs (CJC-1295, sermorelin, tesamorelin) act at a completely separate receptor — GHRHR — signaling through the Gs/cAMP/PKA pathway. On pituitary somatotroph cells, these two intracellular pathways converge on calcium-regulated GH vesicle exocytosis. The independent signal inputs produce supraadditive (synergistic) GH release amplitude — the pharmacological basis of the well-replicated GHRH + GHRP combination protocol.
Q: What distinguishes hexarelin from ipamorelin, GHRP-6, and GHRP-2 as a research compound?Hexarelin has documented binding at the CD36 scavenger receptor (a non-GHS-R1a target) and shows GHS-R1a expression in cardiac tissue. This has positioned hexarelin as a tool in cardioprotective and cardiac GHS-R biology research — a research application not generally shared by ipamorelin, GHRP-6, or GHRP-2. Published ischemia-reperfusion and cardiac function models using hexarelin take advantage of this dual-target pharmacology. For research designs that specifically target cardiac GHS-R1a or CD36-mediated mechanisms, hexarelin is the appropriate GHRP selection.
See Also
- Peptide Half-Life Reference — compiled pharmacokinetic data across 20+ peptides including all four GHRPs
- GHRH Analog Comparison — sermorelin, CJC-1295, and tesamorelin for GHRH + GHRP combination research designs
- Lab Testing & Verified Purity — HPLC and LC-MS testing methodology for research peptides
- How to Verify a Research Peptide COA — batch documentation and certificate validation
- Peptide Storage & Stability — stability windows for GHRP research stocks
- How to Reconstitute Research Peptides — standard laboratory reconstitution workflow
All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.